GlaxoSmithKline (GSK)’s B7-H3-targeted antibody-drug conjugate (ADC), GSK’227 has gained priority medicines (PRIME) ...

The CHMP recommends marketing approval to GSK's Vocabria plus JNJ's Rekambys for treating HIV-1 infection in adolescents aged 12 years and older.

GlaxoSmithKline ( ($GB:GSK) ) has provided an announcement. GSK announced that its B7-H3-targeted antibody-drug conjugate, GSK’227, has received ...

In one of the final steps before a marketing authorization decision by the European Medicines Agency, it recommended ...

The global opioid use disorder treatment market is poised for significant growth, with an expected market size of USD 3.07 ...

GSK (GSK) announced that the European Medicines Agency, EMA, has granted Priority Medicines, PRIME, Designation for GSK5764227, its ...

GSK's cancer drug Jemperli cleared an important hurdle ahead of potentially expanding its European Union marketing permission, in a boost to the pharmaceutical giant's oncology pipeline.

London: GSK plc has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for ...

GSK (GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer (PFE) and Shionogi as ...

GSK has made the decision to withdraw Jesduvroq (daprodustat) from the US market. Approved in 2023, Jesduvroq, (HIF-PHI), is ...

US FDA grants breakthrough therapy designation to GSK’s Jemperli for locally advanced dMMR/MSI-H rectal cancer: London, UK Tuesday, December 17, 2024, 09:00 Hrs [IST] GSK plc an ...

GSK’s B7-H3-targeted ADC, GSK’227, receives EMA PRIME designation in relapsed extensive-stage small-cell lung cancer: London, UK Tuesday, December 17, 2024, 12:00 Hrs [IST] GS ...